Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNEX-X long-term safety extension of BI 425809 in schizophrenia
2020-003745-11Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of treatment-emergent adverse events. Started Jun 2021; status: active.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2020-003745-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003745-11.